Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2017

View Archived Issues

FRMPD4 gene found to be associated with differential sex risk in multiple sclerosis

Financing to support ADC Therapeutics' pipeline of antibody-drug conjugates

Global Blood Therapeutics discontinues IPF program

Finch Therapeutics and Crestovo merge to form Finch Therapeutics Group

Favorable safety seen with AB-423 in healthy volunteers

Enanta Pharmaceuticals reports phase Ib/b trial results for lead FXR agonist

Agenus launches new subsidiary

Novel GLP-1-dexamethasone conjugates reverse immune-metabolic dysfunction and obesity

Mitochondria imaging with [18F]TAP-031 shows promise

Eisai and Biogen expand Alzheimer's collaboration agreement

FDA grants QIDP and fast track designations to Aemcolo for traveler's diarrhea

Cerveau signs license and supply agreement with AbbVie for use of [18F]MK-6240

Promising topline results from phase III ARROW study of once-weekly Kyprolis

FDA grants orphan drug status to RedHill Biopharma's Mesupron

FDA approves Soliris for AchR antibody-positive generalized myasthenia gravis

New gene therapy involving miR-132 shows promise for Huntington's disease

Topline results from phase III PEPITES study of Viaskin Peanut

GlaxoSmithKline patents hSTING modulators

Wilson Therapeutics to initiate pivotal phase III FOCuS study of WTX-101 in Wilson disease

GPR119 agonists presented by Mankind Pharma

Kitasato Institute and Sumitomo Dainippon sign antimicrobial resistance joint research agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...